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ABSTRACT
The ability to identify and maintain mesenchymal stem cells
in vitro is a prerequisite for the ex vivo expansion of cells
capable of effecting mesenchymal tissue regeneration. The
aim of this investigation was to develop an assay to enrich
and ultimately purify mesenchymal stem cells. To enrich the
population of mesenchymal stem cell-like cells, rats or mice
were administered 5-fluorouracil (5-FU) in vivo. Limiting
dilution analysis demonstrated that 5-FU-treated bone mar-
row had the potential to form colony-forming units-fibro-
blastic (CFU-F) at a 10-fold or sixfold enrichment compared
to normal bone marrow in rats or mice, respectively. In vivo
and in vitro differentiation assays supported the enrichment
and purification effects. In vitro, bone marrow cultures
from 5-FU-treated bone marrow demonstrated lineage-spe-
cific gene expression in lineage-specific medium conditions
in contrast to the multilineage gene expression of control
bone marrow cultures. In vivo implantation of 5-FU-treated
cells that were not expanded in culture generated ossicles
containing an intact bone cortex and mature hematopoietic
components, whereas non-5-FU-treated bone marrow only
formed fibrous tissues. Our results demonstrate that enrich-
ment of a quiescent cell population in the bone marrow by in
vivo treatment of 5-FU spares those undifferentiated mes-
enchymal stem cells and influences the differentiation of
bone marrow stromal cells in vitro and in vivo. This pro-
spective identification of a population of mesenchymal cells
from the marrow that maintain their multilineage potential
should lead to more focused studies on the characterization
of a true mesenchymal stem cell. STEM CELLS 2006;24:
1573–1582
INTRODUCTION
Identification of stem cells or early lineage cells is often depen-
dent on cell surface markers that designate the expression of
antigens associated with states of activation, function, or differ-
entiation [1–3]. Because morphological identification of early
lineage cells is not reliable, a detailed knowledge of molecular
function, including enzymatic and secondary markers of differ-
entiation, is necessary. Stem cell identification by definition
relies on the demonstration of the production of lineage-com-
mitted progeny. For hematopoietic stem cells (HSCs), the ex-
pression of CD34, c-kit, and a complex combination of lineage-
committed markers of mature lineages (lin) have served as the
basis of stem cell isolation [4, 5]. However, to date, the most
effective means to distinguish HSCs from progenitor cells is the
use of relatively simple combinations of signaling lymphocyte
activation molecule family receptors expressed on HSCs [6].
The use of in vitro assays for identification of stem cells has
been challenging [7–11]. Markers change with time in culture
and may be linked to the supportive niche that stem cells
occupy. Experimental in vitro end points including long-term
culture-initiating cells, very-long-term culture-initiating cells,
and cobblestone area have been proposed as surrogate markers
for in vivo function [12, 13]. In contrast, in vivo assays for
function of HSCs are the most rigorous and reliable, the pre-
eminent of which are defined using a competitive repopulation
assay, also referred to as severe combined immunodeficient
(SCID)-repopulating assays [14, 15].
Recently, the concept of mesenchymal stem cell transplan-
tation for the treatment of a variety of developmental and
acquired anomalies has gained significant attention [8, 16–19].
The ability to move forward with these therapies, however, is
impeded by the inability to definitively identify and characterize
the putative mesenchymal stem cell (MSC). Despite the lack of
cellular and molecular tools to make these determinations, it is
known that a cell population with MSC-like characteristics can
be isolated based on its ability to adhere to plastic and may be
partially purified by separation techniques [7, 20–22]. Although
bone marrow stromal cells (BMSCs) have the potential to
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differentiate into specialized cells of mesenchymal origin, in-
cluding adipocytes, chondrocytes, myoblasts, and osteoblasts
[23–29], studies have demonstrated that normal BMSCs are
quite rare. They are present at low frequency in bone marrow
and may be found in the circulation in small numbers [30].
BMSCs can be expanded to great numbers by in vitro culture;
however, such a step is time-consuming and expensive and risks
cell contamination. Most important, as these cells gain or lose
their differentiation potential during long-term culture, the abil-
ity to maintain or expand stem cells without adequate in vitro or
in vivo assays hinders the ability to identify putative stem cells
as true stem cells. For identification of HSCs, the answer has
been to eliminate the tissue through lethal levels of radiation.
For mesenchymal stem cells or their immediate progeny, this
approach is not feasible because of the lack of an assay com-
parable to the competitive repopulation assay.
The ability to identify and maintain early mesenchymal cells
with stem cell-like activity in vitro is a prerequisite for the ex
vivo expansion of cells capable of effecting mesenchymal tissue
repair. The aim of this investigation was to develop an in vivo
assay for MSCs similar to the SCID-repopulating assay for
HSCs. It has been previously demonstrated that in vivo treat-
ment with 5-fluorouracil (5-FU), a nucleotide analogue that is
incorporated into DNA during the S-phase of the cell cycle leads
to cell death of cycling cells and enhances the osteogenic
potential of stromal cells in vitro [10, 31]. We therefore sought
to determine whether such a population of cells would maintain
its stem cell-like activity in vivo prior to any cell culture and
begin characterizing this enriched stem cell population.
Using in vitro limiting dilution analysis and in vivo implan-
tation of cells derived from 5 FU-treated animals, we greatly
enriched the cell population capable of forming bone in vivo and
found that transplants of noncultured cells generated bone mar-
row-containing ossicles exhibiting cortical bone and mature
bone marrow structures including adipocytes and chondrocytes.
Our findings also provide evidence that 5-FU spared those
undifferentiated mesenchymal stem cells in vivo and influenced
the differentiation of BMSCs in vitro.
MATERIALS AND METHODS
Animals
Marrow donor animals (8-week-old BALB/c mice and 7- to
8-week-old Fischer rats) were obtained from Charles River
Laboratories (Wilmington, MA, http://www.criver.com). Ani-
mals were caged under standard conditions and fed a laboratory
diet and tap water ad libitum. Care and use of the laboratory
animals followed the guidelines established by the University of
Michigan Committee for the Use and Care of Animals.
5-FU Treatment
One hundred milliliters (wt/vol) 5-FU (American Pharmaceuti-
cal Partners, Inc., Schaumburg, IL, http://www.appdrugs.com)
was administrated intravenously via the lateral tail vein at a dose
of 150 mg/kg (mice) or 50 mg/kg (rats) body weight 5 days prior
to marrow harvest. Control animals were injected with an equal
volume of 0.9% sodium chloride vehicle solution. Marrow
donor animals were euthanized by CO2 inhalation, followed by
cervical dislocation, and the bone marrow was harvested under
sterile conditions.
Bone Marrow Cell Preparation
The femora, tibia, and humera of donor animals were excised,
and adherent tissue was dissected. The marrow was expelled
using a flushing stream of Hank’s buffer salt solution (Gibco,
Grand Island, NY, http://www.invitrogen.com) delivered from a
5-ml syringe fitted with a 23-gauge needle. A single-cell sus-
pension was obtained by gentle agitation through the syringe.
Debris and remaining cellular aggregates were removed by
passing the cell suspension over a 70-mesh nylon cell strainer
(BD Biosciences, San Diego, http://www.bdbiosciences.com).
Cell Culture
Bone marrow cells were resuspended in alpha modified Eagle’s
medium (-MEM; Gibco) supplemented with 15% fetal calf
serum (FCS; Gibco), 1% penicillin and streptomycin, L-ascorbic
acid-2-phosphate (50 mg/l; Wako Inc., Osaka, Japan, http://
www.wako-chem.co/jp/english), and -glycerophosphate (10
mM; Sigma-Aldrich, St. Louis, http://www.sigmaaldrich.com)
and plated into flat-bottom 96-well plates at varying cell num-
bers. On day 5, 50% of the medium was replaced with fresh
medium, and the total culture medium was replaced every 3
days thereafter.
Limiting Dilution Analysis
Bone marrow cell suspensions were density centrifuged on 70%
Ficoll. Log serial dilutions of the experimental marrow popula-
tions were placed into 10 to 20 replicate wells in a total of 200
l of medium. Half the medium was replaced at weekly inter-
vals. At the conclusion, the wells were stained with crystal
violet. By enumerating each colony assay as “positive” (7
cells clustered in one colony) or “negative” (7 cells present in
one colony) for colony-forming unit-fibroblast (CFU-F), the
frequency of progenitor cells in the undiluted starting population
was calculated (L-Calc Software; StemCell Technologies, Van-
couver, BC, Canada, http://www.stemcell.com). The number of
cells required to form one CFU-F, which reflects the proportion
of mesenchymal progenitor/stem cells in the entire bone marrow
population, was then determined from the point at which the line
crossed the 37% level. Based on a Possion’s distribution of
progenitor cells, F0  37% corresponds to the dilution at which
statistically there is one progenitor cell per well [31].
In Vivo Assessment of Multilineage Stem
Cell Activity
BMSCs (5-FU-treated or control) were assessed for their poten-
tial to form bony ossicles after transplantation in immunodefi-
cient mice. Bone marrow from 5-FU-treated and non-5-FU-
treated rats or mice was collected individually. Numbers of
nucleated bone marrow cells ranging from 0, 0.125, 0.25, 0.5, 1,
2, to 4 million were incorporated into a gelatin sponge (Gel-
foam; Pharmacia & Upjohn, Kalamazoo, MI, http://www.
pharmacia.com). These cell/scaffold constructs were trans-
planted subcutaneously into 5-week-old male mice (NIH-bg-nu-
xid BR; Harlan Sprague Dawley, Indianapolis, http://
www.harlan.com). The mice were anesthetized by
intraperitoneal injection of an anesthetic cocktail (75 mg/kg
Ketamine, 10 mg/kg Xylazine of body weight). A skin incision
was made on the dorsal surface of each mouse, and four
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subcutaneous pockets per mouse were created by blunt dissec-
tion. A single implant was placed into each pocket, and incisions
were closed with surgical staples [17, 18].
Sample Harvest and Evaluation
The implants were harvested 5 weeks after surgery and fixed in
aqueous buffered zinc formalin for 24 hours at 4°C. For micro-
computed tomography (CT) analysis, specimens were scanned
at a 8.93-m voxel resolution on an EVS Corporation CT
scanner (London, ON, Canada, http://www.biodevicesbiz.com),
with a total of 667 slices per scan. GEMS MicroView software
was used to make a three-dimensional reconstruction from the
set of scans. A fixed threshold (1,500) was used to extract the
mineralized bone phase and actual bone volume, and bone
mineral density (BMD) was calculated. For histology, the spec-
imens were decalcified for 3 days in 10% formic acid and
embedded in paraffin, and 5-m serial sections were prepared
and stained with hematoxylin/eosin.
Proliferation and Differentiation Assays of Bone
Marrow Cells
Cell proliferation was measured by a colorimetric method using a
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-
sulfonphenyl)-2H-tetrazolium (MTS tetrazolium) compound (Cell-
Titer 96 Aqueous One Solution Cell Proliferation Assay; Promega,
Madison, WI, http://www.promega.com). Bone marrow cell sus-
pensions were density centrifuged on 70% Ficoll to remove red
blood cells, and approximately 400,000 nucleated cells/well were
seeded onto 96-well tissue culture plates. Cells were grown for
various time points in -MEM supplemented with 10% FBS and
1% Pen/Strep with the culture medium changed every other day.
On the day of the proliferation assay, the culture medium was
aspirated and replaced with 100 l of fresh medium. Twenty l of
MTS reagent was added, and cells were allowed to incubate for 2
hours at 37°C in a humidified CO2 (5%) atmosphere. The amount
of soluble formazan product produced by the reduction of MTS by
metabolically active cells was measured by a 96-well spectropho-
tometer at 490 nm absorbance.
For the in vitro osteogenesis assay, the cultures were incu-
bated in Dulbecco’s modified Eagle’s medium (DMEM) that
was supplemented with 15% FCS, 100 U/ml penicillin, 100
g/ml streptomycin, 10 mM -glycerophosphate, 108 M dexa-
methasone (Decadron; Merck & Co., Inc., Whitehouse Station,
NJ, http://www.merck.com), and 0.5 M ascorbate-2-phos-
phate. The medium was changed two times per week for 3
weeks. The cells were fixed with 10% formalin for 20 minutes
at room temperature and stained with 1% silver nitrate for 20
minutes at room temperature (von Kossa’s staining) to identify
mineralized nodules.
For adipogenesis, the cultures were incubated in DMEM
that was supplemented with 15% FCS, 100 U/ml penicillin, 100
g/ml streptomycin, 12 mM L-glutamine, 5 g/ml insulin
(Gibco), 50 M indomethacin (Sigma), 106 M dexametha-
sone, and 0.5 M 3-isobutyl-1-methylxanthine (IBMX; Sigma).
Fixed cells were stained with Oil Red (Sigma) in ethanol for 20
minutes at RT.
For chondrocyte differentiation, the cultures were incubated
in DMEM that was supplemented with 15% FCS, 100 U/ml
penicillin, 100 g/ml streptomycin, 10 ng/ml TGF-1 (BD
Biosciences), 5 g/ml insulin, 1  107 M dexamethasone, 0.4
mM proline (Gibco), 0.5 M ascorbate-2-phosphate, 0.1 mM
MEM-nonessential AA (Gibco). The medium was changed two
times per week for 3 weeks. Fixed cells were stained with
Safranin O (Sigma) in ethanol for 20 minutes at RT.
RNA Extraction, cDNA Synthesis, and RT-PCR
Analysis of Various Differentiation Gene Markers in
Bone Marrow Cells
To investigate gene expression in bone marrow cells after in
vivo 5-FU treatment, various gene markers of differentiation
were analyzed. RT-polymerase chain reaction (PCR) analysis
using total RNA was performed in uncultured bone marrow
cells and bone marrow cells cultured in specific differentiation
medium at harvest and day 21. Total RNA was extracted with
Trizol reagent (Invitrogen, Carlsbad, CA) and treated with 1 U
of DNase I at room temperature for 15 minutes to digest any
contaminating DNA. Aliquots containing 1 g total RNA were
used to prepare cDNA. The PCR was carried out with Taq DNA
polymerase (Invitrogen). The reaction profile was 94°C for 30
seconds, 55–58°C for 1 minute, and 72°C for 1 minute. We used
35 cycles for all the assays. D-Glyceraldehyde-2-phosphate de-
hydrogenase was used as an internal control. PCR products were
separated by electrophoresis in 1.8% agarose gels and visualized
by ethidium bromide staining.
Statistics
The mean and standard derivation is reported at each group for
bone volumes and BMD by CT. The Student’s t test was used
to determine significant differences between groups. We applied
curve simulations to calculate the frequency of CFU-F with the
SPSS program (version 10; SPSS Inc., Chicago, http://www.
spss.com). Differences were considered significant at p  .05.
RESULTS
Frequency of CFU-F
The aim of this study was to develop an in vivo correlate to the
SCID-repopulating assay for MSCs (Fig. 1). Based on what is
known in other stem cell systems, we reasoned that most MSCs
at any given time would be cycling slowly and be of low
density. Therefore, we developed a strategy to enrich for a
population that contained cells with MSC-like activity and
tested their potential in vitro and in vivo.
Initial investigations were performed to identify the fre-
quency of CFU-F derived from rat and mouse bone marrow
using standard limiting dilution methods. Based on Poisson
Table 1. Limiting dilution analysis and CFU-F formation
demonstrate significant enrichment of mesenchymal stem cells in
5-FU-treated bone marrow
Species
5-FU
treatment Frequency of CFU-F
Rat  1/97,640 (1/128,766–1/74,029)
Rat  1/9,347 (1/9,895–1/8,831)a
Mouse  1/59,653 (1/103,276–1/34,451)
Mouse  1/10,106 (1/10,290–1/9,927)a
a p  .05.
Abbreviations: 5-FU, 5-fluorouracil; CFU-F, colony forming unit-
fibroblast.
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distribution [32], the intersection of the corrected line with a 37%
level demonstrated that under standard culture conditions, one of
every 9.7  104 nucleated rat cells from control bone marrow had
the capacity to form a CFU-F. In contrast, the frequency of CFU-F
in mice was slightly higher, demonstrating a rate of one per 6.0 
104 nucleated cells (Table 1). Treating animals with 5-FU led to a
significant increase in the frequency of CFU-Fs. CFU-Fs generated
from bone marrow cells increased to one of 9.3  103 nucleated
cells in rats or one of 10.1  103 cells in mice. These data
demonstrate that treatment of animals with 5-FU increased the
frequency of CFU-F formation from bone marrow cells sixfold in
mice and 10-fold in rats (Table 1).
In Vivo Determination of Multilineage Stem
Cell Activity
Our findings were similar to a previous report and demonstrated
that in vivo treatment of animals with 5-FU and subsequent
separation in Ficoll increased the frequency of CFU-F in vitro
[31]. At least two possibilities exist to account for these obser-
vations. The first is that the quiescent state of the cells spares
them from the metabolic poison, or that following 5-FU treat-
ment the stem cells have the capacity to expand in vivo. In either
case, CFU-F frequency would increase.
To first verify that CFU-F numbers reflect stem cell activities,
nucleated low-density donor marrow cells were isolated from rats
or mice following in vivo 5-FU treatment. Recipient immunodefi-
cient mice were immediately transplanted with limiting dilutions of
low-density mononuclear cells in gelatin sponges over a dose range
of 0–4 106 cells (Fig. 2A, 2B). After 5 weeks in vivo the tissues
were recovered, radiographed, and prepared for histology. Gross
inspection of 5-week in vivo samples demonstrated that transplants
containing 5 105 cells formed small, avascular nodules (data not
shown). For implants derived from 5-FU treated animals, the 2
106 and 4 106 cell groups formed organized tissue with visible
vascular invasion. Sponge implants containing vehicle-treated mar-
row formed only whitish soft tissue nodules.
Histological examination of the control sponges transplanted
without bone marrow cells resulted in only low levels of neutro-
phils and connective tissue ingrowth (data not shown). Implanta-
tion of 5  105 cells in either group also failed to demonstrate
specific tissue regeneration and consisted of loosely organized
connective tissue and residual collagen scaffold material (Fig. 2).
Implantation of 1.0  106 cells from the 5-FU-treated rats pro-
duced small focal areas of hypertrophic cells that resembled carti-
lage-like tissue; however, molecular analyses did not support this
morphologic finding (Fig. 2A). At 2 106 cells/implant the 5-FU-
treated groups demonstrated significant new bone formation, adi-
pocytes, and the recruitment of marrow. Further enhancement of
bone/marrow organ development, including an intact cortex-like
structures, medullary adipose tissue, and a mature hematopoietic
marrow cavity was observed following implantation of 4  106
5-FU-treated cells. The extent of osteogenesis was dependent on
the number of cells seeded, with the 4 106 nucleated cell groups
demonstrating more intact cortex-like structure, thicker of trabec-
ulae, and more bone marrow than those of 2  106 nucleated cell
groups. Such bone formation was not observed when noncul-
tured bone marrow cells from control animals were transplanted
(Fig. 2A).
Results from transplanted mouse marrow were comparable
with those observed for samples derived from rat marrow (Fig.
2B). Distinct multilineage tissue formation was consistently
observed when 2–4 106 cells from 5-FU-treated animals were
incorporated into implant sponges. Each of the implants had
distinctly thickened cortexes and well-developed marrow
Figure 1. Schematic of the in vivo 5-FU treatment strategy to enrich cells for MSC characteristics in bone marrow. Fischer rats and BALB/c mice
were injected intravenously with 5-FU. Bone marrow was harvested 5 days post-treatment and was either immediately transplanted to severe
combined immunodeficient mice at 0.125, 0.25, 0.5, 1, 2, or 4  106 nucleated cells per implant or cultured ex vivo. The newly formed tissues were
measured by CT, and histologic analysis was performed to identify the constitution of the implants. In vitro evaluation included limiting dilution
assay for CFU-F frequency, MTS for proliferation, and differentiation staining under specific induction medium. For gene expression studies, RNA
from both fresh medium and BMSCs cultured in lineage specific differentiation medium were extracted and subjected to RT-PCR analysis.
Abbreviations: 5-FU, 5-fluorouracil; BM, bone marrow; CFU-F, colony forming units-fibroblastic; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl) 2-(4-sulfonphenyl)-2H-tetrazolium; RT-PCR, reverse transcription-polymerase chain reaction.
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structures. At cell densities lower than 1  106 per implant, less
consistent results were observed and implants were comprised
of loosely organized connective tissue.
Micro-CT Images and Quantitative Analysis
Microcomputed tomographic (CT) analysis of the recovered os-
sicles revealed intact bone cortexes with a well-developed marrow
cavity (Fig. 2A, 2B, inserts). By comparing the bone volume of
each group, there was a significantly greater volume in implants
from 4 106 mouse-nucleated cells than those tissues generated by
implants with 2  106 mouse cells (1.35  0.03 vs. 0.35  0.02
mm3, Fig. 2B, p  .05). However, such differences were not
observed in rat samples (0.34  0.03 vs. 0.33  0.01 mm3, Fig.
2A), suggesting that the timing of cell differentiation and extent of
bone mineralization are different between the two species in this
model system. Quantitative analysis by CT demonstrated signif-
icantly higher bone mineral density (BMD) values in 4  106 cell
implants than that of 2  106 cell implants. This difference was
consistent in both rat and mouse groups (142.26  6.37 vs.
96.72 22.76 mg/mm3 in rat; 227.13 54.25 vs. 128.16 11.24
mg/mm3 in mouse p  .05) (Fig. 3).
MTS Assays of Both Rat 5-FU-Treated Bone
Marrow Cells
One explanation for the increase in CFU-F frequency and tissue
generated by implanted cells is that 5-FU either spared the stem
Figure 2. In vivo differentiation of bone marrow cells. Donor low-density marrow cells were isolated from rats (A) or mice (B) treated with 5-FU or vehicle.
Recipient immunodeficient mice were transplanted with limiting dilutions of low-density mononuclear cells in gelatin sponges over a dose range of 0–4
106 cells/implant. After 5 weeks, the tissues were recovered, radiographed, and prepared for histology. In each case, sponges alone failed to demonstrate any
organized tissue regeneration (data not presented). H&E sections presented at a magnification of 100 for sponges containing 5  105 cells also failed to
demonstrate distinct tissue generation. Implantation of 1.0  106 cells from the 5-FU-treated group produced hypertrophic-like chondrocytes, but the
vehicle-treated group did not. At 2  106 cells/implant, the 5-FU-treated groups demonstrated significant bone deposition resulting from osteoblastic
differentiation, adipocytes, and the recruitment of marrow, whereas the control did not. Further enhancement of marrow organ development including an
intact cortex, medullarlary adipose tissue, and a mature marrow cavity occurred following implantation of 4  106 5-FU-treated cells, which was not seen
in the vehicle-treated animals. Three-dimensional cross-sectional CT views of implants also identified radiopaque bone in 5-FU-treated bone marrow
implants at two and 4 million implants (insert). The CT threshold was set at 1,500. Abbreviations: 5-FU, 5-fluorouracil; BM, bone marrow.
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cells or allowed the expansion in their numbers. As an initial
attempt to explore whether the proliferative state of the 5-FU-
recovered cells was different from vehicle-treated cells, prolif-
eration assays were performed. Recovered cells were plated at
low density, and proliferation was measured spectrophotometri-
cally. In this assay, both rat and mouse BMSCs proliferated
slowly when cultured in vitro (Fig. 4).
In Vitro Cell Differentiation
Another possible way that 5-FU treatment may have increased
the CFU-F frequency and the complexity of the tissue generated
in vivo is that the drug spared the stem cells that were in a
relative quiescent state, thus increasing the frequency of stem
cells per marrow cell. Should this possibility be correct, one
would expect that the capacity for multilineage tissue generation
would remain intact following 5-FU treatment. To evaluate this
possibility in vitro, the differentiation potential of the in vivo
5-FU-treated bone marrow cells was compared with those de-
rived from control animals cultured under adipogenic, osteo-
genic, or chondrogenic conditions. After 3 weeks in lineage-
specific culture conditions, the expanded cells from both the
5-FU-treated and control animals were characterized. We found
that lineage-specific induction was maintained for each culture
condition. Adipogenic induction was apparent by the accumu-
lation of lipid-rich vacuoles within cells (Fig. 5; Oil Red stain-
ing) following culture. Interestingly, 5-FU-treated bone marrow
cells formed significant larger aggregates of mineralized nod-
ules with von Kossa staining compared with control. Cells also
showed positive staining for chondrocytic proteoglycans in both
the 5-FU and control groups (Fig. 5; Safranin O staining).
Evaluation of Lineage Commitment
To determine the long-term changes of gene expression by 5-FU
treatment, we cultured the cells under adipogenic, chondrogenic,
and osteogenic conditions. Bone marrow treated with vehicle
alone from either rat or mouse displayed an overlapping gene
expression pattern when placed in lineage specific culture con-
ditions. For example, multidifferentiation gene expression was
observed for rat marrow cells placed in osteogenic or chondro-
genic conditions. 5-FU-treated bone marrow cells, however,
displayed a more restricted phenotype following lineage differ-
entiation (Fig. 6A, 6B). Murine marrow treated with 5-FU
demonstrated a high degree of fidelity to lineage commitment
compared with the more promiscuous phenotype displayed by
the untreated cells. These findings confirm our hypothesis that
5-FU spared the most undifferentiated mesenchymal stem cells in
vivo but may have eliminated progenitor cells with multilineage
commitment, resulting in the purification of a less committed
cell.
DISCUSSION
The identification and purification of mesenchymal stem cells
has been hampered by the lack of in vitro and in vivo assays that
permit the rigorous identification of stem cells from mesenchy-
mal tissues. For some time, it has been known that hemopoietic
marrow is formed in bone ossicles formed by transplanted
BMSCs [23, 25, 33–38]. The blood cells formed in these os-
sicles display multilineage characteristics by representing all the
mature blood cell compartments [39]. In addition, the bone
organs are fully integrated with the hematopoietic demands
placed on the organism [40]. When bone matrix or purified
bone-derived proteins are implanted into subdermal spaces of
rodents [33, 41, 42], bone proteins induce the recruitment of
pluripotent mesenchymal and circulating hematopoietic cells of
host origin to form the developing organ. Recently, it has been
demonstrated that syngenic donor BMSCs also form bone os-
sicles in a murine host [24]. Here, the mixed BMSCs establish
a microenvironment that supports host-derived hematopoiesis
and contains multilineaged committed cells (adipocytes, chon-
drocytes, osteoblasts) derived from donor cells [3, 29, 40, 41,
43]. Together, these findings indicate that BMSCs cultured in
vitro maintain to some degree the potential to form multilineage
tissue aggregates or marrow organs. Yet rigorous determination
of the identity of MSCs has not been achieved.
Although there has been some success in expanding ro-
dent and human BMSCs that retain the capacity for miner-
alization in vitro and bone formation in vivo, the problems of
cellular heterogeneity and lack of predictors of success will
Figure 3. Quantative analysis of 5-FU-treated BM implants, measured by micro-CT. (A): The comparison of bone volume (mm3) in mouse and rat
BM cell implants, †, p  .01 at 4  106 in the mouse BM cell group. (B): The comparison of BMD in both rat and mouse cell implants. *, **, p 
.05 for 4  106 mouse BM group relative to both mouse 2  106 and rat 4  106 group. Abbreviations: BM, bone marrow; BMD, bone mineral
density.
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ultimately impede the clinical utility of these cells. Several in
vitro experimental manipulations have been performed in
attempts to characterize BMSCs [3, 41, 43–50]. However, the
in vitro manipulation of the cells, without a clear identifica-
tion of the stem cell phenotype, limits scientific advancement
or potential therapies.
The strategy of using 5-FU and low-density separation in-
creased the frequency of CFU-F in vitro and increased the
frequency of cells capable of forming bony organs in vivo
without the need to expand the progenitor cells in vitro. We
found that the transplantation of 2 million unfractionated nucle-
ated cells from 5-FU-treated bone marrow generated intact
ossicles containing a mineralized cortex, trabecular structure,
fat, mature bone marrow, and blood vessels (Fig. 2). Based on
the enrichment defined in Table 1, it is estimated that 200 to 400
CFU-F cells can form such ossicles, indicating there is a
minimal requirement of cell numbers for cell interaction to
constitute an appropriate microenvironment to produce bone. In
comparison, non-5-FU-treated bone marrow transplantation
only formed fibrous-like tissues, indicating the enrichment and
purification effects of 5-FU play an important role in osteogen-
esis in vivo.
Several possibilities exist to account for these observations.
The vast majority of available data suggests that hematopoietic
and possibly mesenchymal stem cells cycle slowly such that at
any given time, the vast majority of the cells are in G0 phase of
the cell cycle. The majority of stem cells would be relatively
resistant to metabolic poisons or treatments that target rapidly
cycling cells. In the case of a single dose of 5-FU, it is possible
that the drug may trigger the release of a quiescent stem cell
pool, resulting in either stem cell expansion or commitment to
progenitor populations to regenerate those damaged cell
Figure 5. Comparison of the differentiation
potential of normal bone marrow and 5-FU-
treated bone marrow cells. Cultured bone
marrow cells from control or 5-FU-treated
rats (A) and mice (B) were tested for the
ability to differentiate in vitro to multiple
lineages at day 21 after culture in lineage
specific medium. Adipogenesis, osteogene-
sis, and chondrogenesis were indicated by Oil
Red, von Kossa, and Safranin O, respec-
tively. Abbreviation: 5-FU, 5-fluorouracil.
Figure 4. Cell proliferation of bone marrow
stromal cells, assessed by MTS analysis.
Samples were harvested on alternating days
for the 1st week, and at days 17 (for rat) and
20 (for mouse) to ensure continued cell via-
bility. No significant differences were ob-
served between 5-FU-treated bone marrow
and control (p  .05). Abbreviations: 5-FU,
5-fluorouracil; MTS, 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-
sulfonphenyl)-2H-tetrazolium; OD, optical
density.
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compartments. Alternatively, it is also possible that stem cells
fail to commit to any of the lineages but rather were enriched on
a per cell basis of the remaining viable cells. From our data, we
cannot distinguish between these two possibilities. Previous ex
vivo approaches using 5-FU-treated mouse bone marrow cells
have enriched the CFU-F and osteogenic progenitor cells by as
much as 12-fold and demonstrated the expression of bone-
specific markers in vitro [31]. Our strategy enriched CFU-F
10-fold in rats and sixfold in mice. In vitro proliferation assays
of the recovered cells indicated no significant differences
between 5-FU treatment and normal BMSCs; however, these
investigations may not have been sensitive enough based on
purity alone to determine differences in stem cell or progenitor
cell behavior.
It was recently reported that 5-FU impaired the stem cell
engraftment functions depending on whether the host animals
were lethally or sublethally conditioned [51]. As such, 5-FU
may activate mesenchymal cells to support hematopoietic stem
cell activities. We observed that 5-FU-treated bone marrow
exerted an enhanced and selective effect on osteogenic differ-
entiation as determined by von Kossa staining of BMSCs cul-
tures in vitro compared with control BMSC cultures. However,
no apparent differences were detected in adipogenic or chon-
drogenic differentiation effects between 5-FU and control
BMSC cultures. The observation of multilineage differentiation
may be due to the presence of multilineage-committed progen-
itor cells, indicating 5-FU functions by sparing and enriching the
stem cells in bone marrow.
We found that bone marrow treated with vehicle alone from
either rat or mouse displayed an overlapping gene expression
pattern when placed in lineage-specific culture conditions.
These data suggest that a large percentage of the progenitors
were heterogeneous at the time of marrow extraction. It would
be expected that a more restricted phenotype would be observed
if more pure cell populations were cultured in lineage-specific
conditions. This, in fact, was observed in this study, when the
enriched cells displayed an enhanced fidelity to lineage com-
mitment compared with the more promiscuous phenotype of the
control cells. These findings support the hypothesis that 5-FU
spared those undifferentiated mesenchymal stem cells in vivo
and eliminated proliferative, lineage promiscuous cells. Thus,
this work links multilineage differentiation in vivo to cell fre-
quency in vitro in both rats and mice. As such, we propose that
this assay may be useful for further isolation and ultimate
characterization of noncultured mesenchymal stem cells, that is,
the correlate to the SCID-repopulating assay used to identify
hematopoietic stem cells.
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